Drug Approval | January 08, 2026
Rapid-acting ADHD treatment Azstarys now approved in China
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
Subscribe To Our Newsletter & Stay Updated
